Fulcrum Therapeutics (Fulcrum Therapeutics) Debt-to-Equity : 0.05 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics Debt-to-Equity?

Fulcrum Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.19 Mil. Fulcrum Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.63 Mil. Fulcrum Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $235.19 Mil. Fulcrum Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Fulcrum Therapeutics's Debt-to-Equity or its related term are showing as below:

FULC' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.02 Max: 0.07
Current: 0.05

During the past 7 years, the highest Debt-to-Equity Ratio of Fulcrum Therapeutics was 0.07. The lowest was 0.00. And the median was 0.02.

FULC's Debt-to-Equity is ranked better than
73.51% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs FULC: 0.05

Fulcrum Therapeutics Debt-to-Equity Historical Data

The historical data trend for Fulcrum Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulcrum Therapeutics Debt-to-Equity Chart

Fulcrum Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.07

0.05

Fulcrum Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.07	0.04	0.04	0.05	0.05

Competitive Comparison of Fulcrum Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Fulcrum Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulcrum Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Fulcrum Therapeutics's Debt-to-Equity falls into.

Fulcrum Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Fulcrum Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.192	+	8.629)	/	235.193
	=	0.05

Fulcrum Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.192	+	8.629)	/	235.193
	=	0.05

Fulcrum Therapeutics (NAS:FULC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Fulcrum Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulcrum Therapeutics (Fulcrum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Landsdowne Street, Cambridge, MA, USA, 02139

Website

https://www.fulcrumtx.com

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company's proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Executives

Alan A Musso	officer: Chief Financial Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir	director, officer: See Remarks	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Greg Tourangeau	officer: Controller	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould	director, officer: President & CEO	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo	officer: Chief Medical Officer	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii	officer: Chief Operating Officer	FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu	officer: Chief Financial Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart	officer: Chief Operating Officer	C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham	officer: Chief Scientific Officer	26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson	officer: VP Finance & Accounting	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139